Log In
Print
BCIQ
Print
Print this Print this
 

Zuplenz, ondansetron

  Manage Alerts
Collapse Summary General Information
Company MonoSol Rx LLC
DescriptionSelective serotonin (5-HT3) receptor antagonist
Molecular Target Serotonin (5-HT3) receptor
Mechanism of ActionSerotonin (5-HT3) receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationEmesis
Indication DetailsPrevent and treat nausea and vomiting; Prevent postoperative chemotherapy-induced and radiotherapy-induced nausea and vomiting
Regulatory Designation
Partner Galena Biopharma Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today